459 related articles for article (PubMed ID: 18798304)
21. [Treatment of metastasized malignant melanoma].
Kamanabrou D
Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
24. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
[TBL] [Abstract][Full Text] [Related]
25. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
Buzaid AC; Legha SS
Semin Oncol; 1994 Dec; 21(6 Suppl 14):23-8. PubMed ID: 7992096
[TBL] [Abstract][Full Text] [Related]
26. Head and neck mucosal melanoma: a 32-year review.
Loree TR; Mullins AP; Spellman J; North JH; Hicks WL
Ear Nose Throat J; 1999 May; 78(5):372-5. PubMed ID: 10355199
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Hess V; Herrmann R; Veelken H; Schwabe M
Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
[TBL] [Abstract][Full Text] [Related]
28. Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine.
Melichar B; Voboril Z; Lojík M; Krajina A
Hepatogastroenterology; 2009; 56(93):1157-62. PubMed ID: 19760961
[TBL] [Abstract][Full Text] [Related]
29. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
O'Day SJ; Gammon G; Boasberg PD; Martin MA; Kristedja TS; Guo M; Stern S; Edwards S; Fournier P; Weisberg M; Cannon M; Fawzy NW; Johnson TD; Essner R; Foshag LJ; Morton DL
J Clin Oncol; 1999 Sep; 17(9):2752-61. PubMed ID: 10561350
[TBL] [Abstract][Full Text] [Related]
30. Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction.
Margolin KA
Cancer; 2004 Aug; 101(3):435-8. PubMed ID: 15274056
[No Abstract] [Full Text] [Related]
31. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
32. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
Bottoni U; Bonaccorsi P; Devirgiliis V; Panasiti V; Borroni RG; Trasimeni G; Clerico R; Calvieri S
Jpn J Clin Oncol; 2005 Sep; 35(9):507-13. PubMed ID: 16120623
[TBL] [Abstract][Full Text] [Related]
33. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study.
Schmidt H; Geertsen PF; Fode K; Rytter C; Bastholt L; von der Maase H
Melanoma Res; 2000 Feb; 10(1):66-77. PubMed ID: 10711642
[TBL] [Abstract][Full Text] [Related]
34. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region.
Owens JM; Roberts DB; Myers JN
Arch Otolaryngol Head Neck Surg; 2003 Aug; 129(8):864-8. PubMed ID: 12925346
[TBL] [Abstract][Full Text] [Related]
35. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
[TBL] [Abstract][Full Text] [Related]
36. Biochemotherapy in patients with metastatic anorectal mucosal melanoma.
Kim KB; Sanguino AM; Hodges C; Papadopoulos NE; Eton O; Camacho LH; Broemeling LD; Johnson MM; Ballo MT; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Prieto VG; Bedikian AY
Cancer; 2004 Apr; 100(7):1478-83. PubMed ID: 15042682
[TBL] [Abstract][Full Text] [Related]
37. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy.
Meleti M; Leemans CR; de Bree R; Vescovi P; Sesenna E; van der Waal I
Head Neck; 2008 Dec; 30(12):1543-51. PubMed ID: 18704960
[TBL] [Abstract][Full Text] [Related]
38. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
39. Clinical results using biochemotherapy as a standard of care in advanced melanoma.
Chapman PB; Panageas KS; Williams L; Wolchok JD; Livingston PO; Quinn C; Hwu WJ
Melanoma Res; 2002 Aug; 12(4):381-7. PubMed ID: 12170188
[TBL] [Abstract][Full Text] [Related]
40. Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
Feun L; Marini A; Moffat F; Savaraj N; Hurley J; Mazumder A
Cancer Invest; 2005; 23(1):3-8. PubMed ID: 15779861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
